➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
McKinsey
Colorcon
Dow
Johnson and Johnson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LINACLOTIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Linaclotide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00402337 ↗ Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation Completed Ironwood Pharmaceuticals, Inc. Phase 2 2006-11-01 The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation.
NCT00460811 ↗ Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Completed Ironwood Pharmaceuticals, Inc. Phase 2 2007-04-01 The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
NCT00730015 ↗ Trial of Linaclotide in Patients With Chronic Constipation Completed Forest Laboratories Phase 3 2008-08-01 The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.
NCT00730015 ↗ Trial of Linaclotide in Patients With Chronic Constipation Completed Ironwood Pharmaceuticals, Inc. Phase 3 2008-08-01 The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.
NCT00730171 ↗ An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Completed Forest Laboratories Phase 3 2008-09-01 The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C)
NCT00730171 ↗ An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Completed Ironwood Pharmaceuticals, Inc. Phase 3 2008-09-01 The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Linaclotide

Condition Name

Condition Name for Linaclotide
Intervention Trials
Chronic Constipation 9
Irritable Bowel Syndrome With Constipation 8
Chronic Idiopathic Constipation 4
Irritable Bowel Syndrome With Constipation (IBS-C) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Linaclotide
Intervention Trials
Constipation 30
Irritable Bowel Syndrome 17
Syndrome 15
Colorectal Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Linaclotide

Trials by Country

Trials by Country for Linaclotide
Location Trials
United States 569
Canada 21
Japan 6
United Kingdom 3
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Linaclotide
Location Trials
Texas 21
Pennsylvania 21
Georgia 20
Florida 20
California 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Linaclotide

Clinical Trial Phase

Clinical Trial Phase for Linaclotide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 15
Phase 2 10
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Linaclotide
Clinical Trial Phase Trials
Completed 19
Not yet recruiting 6
Active, not recruiting 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Linaclotide

Sponsor Name

Sponsor Name for Linaclotide
Sponsor Trials
Ironwood Pharmaceuticals, Inc. 21
Forest Laboratories 13
Astellas Pharma Inc 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Linaclotide
Sponsor Trials
Industry 48
Other 8
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Merck
Dow
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.